Bristol Myers Squibb CEO Chris Boerner sits down with CNBC's Angelica Peebles at the American Society of Clinical Oncology's ...

Bristol Myers Squibb has an attractive 4.4% yield, and its 16x P/E is below the pharma average of 24x.

Bristol Myers Squibb (BMY) looks undervalued: 4 near-term pipeline catalysts and DCF imply ~20% upside, plus 4.35% yield.

Buy Bristol Myers Squibb (BMY) on the dip: low 8.7x forward P/E, 4.6% yield, 9% sales growth and key H2 2026 readouts.

Called mezigdomide, the drug is one of two protein-degrading medicines Bristol Myers hopes to soon position as successors to ...

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a ...

Bristol Myers Squibb has won U.S. Food and Drug Administration priority review for its application seeking expanded approval of its Camzyos heart drug for adolescents with symptomatic obstructive ...

Bristol-Myers Squibb (NYSE:BMY) plans to present extensive new clinical data at the 2026 ASCO Annual Meeting. The company ...

The latest medicines from Bristol Myers Squibb (BMY +0.47%) were the driving force behind the company's considerable share price gain on Thursday. The pharmaceutical company's fir ...

By Michael Erman May 29 (Reuters) - Bristol Myers Squibb said on Friday that its experimental oral drug mezigdomide delayed disease progression in a late-stage trial of multiple myeloma patients whose ...

Bristol Myers Squibb came into the quarter with fairly modest expectations hanging over it. Instead, the company delivered ...